Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases

13-jul-2017 | Revista: Future Oncology

Aranda E (1), Aparicio J (2), Bilbao JI (3), Alfonso PG (4), Maurel J (5), Rodríguez J (6), Sangro B (7), Vieitez JM (8), Feliu J (9). (1) Department of Medical Oncology, Hospital Universitario Reina Sofía, CIBERONC, IMIBIC, UCO, Córdoba, Spain.
(2) Department of Medical Oncology, Hospital Universitari I Politecnic La Fe, Valencia, Spain.
(3) Department of Vascular & Interventional Radiology, Clínica Universidad de Navarra, Navarra, Spain.
(4) Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
(5) Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
(6) Department of Medical Oncology, Clínica Universitaria de Navarra, Navarra, Spain.
(7) Liver Unit & HPB Oncology Area, Clínica Universitaria de Navarra-IDISNA-CIBEREHD, Pamplona, Spain.
(8) Department of Medical Oncology, Hospital Universitario Central de Asturias, Asturias, Spain.
(9) Department of Medical Oncology, Hospital Universitario La Paz, CIBERONC, Madrid, Spain.


RESUMEN

A Spanish expert panel reviewed current evidence for the use of SIR-Spheres Y-90 resin microspheres in patients with chemotherapy refractory/intolerant unresectable colorectal liver metastases.

Substantial evidence for its efficacy and safety is available from a randomized controlled study, retrospective comparative studies and several single arm studies.

Clinical evidence data obtained from more than 1500 patients have led to the inclusion of selective internal radiation therapy in the 2016 ESMO Clinical Guidelines as third-line treatment.

This publication results from an expert panel meeting, where published evidence and author's experiences were shared to position SIR-Spheres Y-90 resin microspheres in Spain for the treatment of chemotherapy refractory/intolerant unresectable colorectal liver metastases, and second, to define the patient subgroup that will benefit the most with this treatment.

CITA DEL ARTÍCULO  Future Oncol. 2017 Jul 13. doi: 10.2217/fon-2017-0220

Nuestros autores